Rejected from Nucleic Acids Research? The 7 Best Journals to Submit Next

The most common rejection reason at NAR is scope. If your paper uses nucleic acid biology as a tool to answer a question in another field (cancer biology, immunology, plant science), NAR's editors will redirect you to a journal in that field. The nucleic acid component needs to be the central scientific contribution, not just the experimental technique.

NAR's database issue is its most competitive section. Submissions are evaluated on utility, novelty, and maintenance commitment. If the editors determined that your database overlaps too much with existing resources, doesn't serve a large enough user community, or lacks a clear maintenance plan, the paper won't make it through. These rejections are almost always final for that specific submission cycle.

For research articles, NAR expects strong mechanistic insight, not just descriptive findings. If your paper reports a new sequence, structure, or interaction without explaining why it matters mechanistically, the reviewers will flag it. NAR also prioritizes papers that introduce new methods or significantly improve existing ones.

NAR reviewers increasingly expect orthogonal validation of key findings, particularly for computational predictions. If your bioinformatics analysis lacks experimental validation, or your structural work doesn't include functional assays, that gap will likely trigger rejection.

Before choosing your next journal, a Nucleic Acids Research manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. Genome Biology

Genome Biology is the strongest alternative for genomics research that NAR rejected. The journal publishes genome-scale studies, new sequencing technologies, and computational methods with biological applications. Its impact factor (~12) is competitive, and the editorial team values papers that combine computational rigor with biological insight. If NAR rejected your paper because the genomics findings weren't sufficiently focused on nucleic acid mechanisms, Genome Biology may be a better fit because it cares more about the biological conclusions than the molecular category of the subject.

Best for: Genomics, epigenomics, single-cell studies, and computational genomics with clear biological applications.

2. Genome Research

Genome Research publishes primary research on the structure, function, and regulation of genomes. It's slightly more focused than Genome Biology on fundamental genome biology rather than tools. If your NAR submission was a genome structure or regulation paper, Genome Research is a natural home. The review process tends to be thorough, and the journal has a strong reputation in the genomics community. Turnaround is typically 8-12 weeks.

Best for: Genome organization, chromatin structure, regulatory genomics, and comparative genomics.

3. RNA

If your NAR paper focused on RNA biology, the journal RNA is the obvious alternative. Published by the RNA Society, it covers everything from RNA structure and catalysis to gene regulation and RNA-based technologies. The acceptance rate (~30%) is more accessible than NAR, and the reviewer pool is deeply specialized in RNA science. Papers that NAR considered too narrow for its broader nucleic acid scope often find a warm reception here.

Best for: RNA structure, splicing, non-coding RNA, RNA processing, and ribozyme catalysis.

4. Bioinformatics

For computational tools and database papers that NAR's web server issue rejected, Bioinformatics (Oxford) is the primary alternative. The journal publishes methods papers, software tools, and algorithm developments across all areas of computational biology. It doesn't have the same annual issue constraint that NAR's database section imposes, which means your submission timeline isn't locked to a yearly cycle. The review process focuses on computational validity and utility rather than biological novelty.

Best for: Software tools, databases, algorithms, and computational pipelines.

5. Journal of Molecular Biology

JMB publishes structural and mechanistic studies of biological macromolecules, including nucleic acids and their protein complexes. If NAR rejected your structural biology paper, JMB may value the detailed structural work more than NAR's broader readership did. The journal has a long history of publishing high-quality structural and biophysical studies. Its acceptance rate is around 30%, and the review process is managed by active researchers in structural biology.

Best for: Structural biology of nucleic acids, protein-DNA/RNA interactions, and molecular mechanisms.

6. PLOS Computational Biology

PLOS Computational Biology covers computational methods applied to biological problems, including genomics, systems biology, and structural modeling. For NAR rejects where the primary contribution is a new algorithm or computational framework, PLOS Comp Bio values methodological innovation and reproducibility. The journal requires code availability and emphasizes open science, which can strengthen your paper if you've already committed to those practices.

Best for: Computational methods, systems biology modeling, algorithm development with biological applications.

7. NAR Genomics and Bioinformatics

NAR's own sister journal publishes genomics and bioinformatics research that falls outside the main journal's scope or competitive threshold. It's fully open access and has a faster review timeline than the parent journal. If NAR's editors suggested this journal in their rejection, take the suggestion seriously. The editorial standards are maintained by the same community, and the journal is growing in visibility. This is particularly useful for database papers that missed the main journal's annual issue deadline.

Best for: Genomics tools, bioinformatics methods, and database papers that narrowly missed NAR's main journal.

Rejected for scope ("not sufficiently focused on nucleic acids")? Go to Genome Biology or Genome Research if the work is genomics-focused. Go to a disease-specific or organism-specific journal if the nucleic acid work was secondary to the biological question.

Database paper rejected from the annual issue? Submit to Bioinformatics or NAR Genomics and Bioinformatics immediately. Don't wait for the next NAR database cycle, as yManusights will be less novel by then.

Rejected for "insufficient mechanistic insight"? Either add the mechanistic experiments and resubmit elsewhere, or target JMB or RNA where the structural and biochemical data may be valued on its own terms.

Rejected for "computational work lacks experimental validation"? Either find a collaborator who can provide validation data, or submit to PLOS Computational Biology or Bioinformatics, where computational papers don't always require wet-lab validation.

Clarify your central contribution. NAR rejections often stem from ambiguity about whether the paper is a methods paper, a database paper, or a research article. Pick one frame and commit to it. If your paper tries to be all three, it won't succeed at any journal.

Strengthen your validation. If reviewers questioned your computational predictions, add experimental validation before resubmitting anywhere. If the experimental paper lacks computational analysis that would strengthen the conclusions, add it. The trend across all journals in this space is toward integrated approaches.

Update your literature review. NAR covers a fast-moving field, and reviewers expect current citations. If your paper doesn't cite relevant work from the past 12 months, it signals that you aren't keeping up with the field. This is fixable in a few hours and can change how reviewers perceive your work.

Reconsider your framing. A paper rejected from NAR for being "too specialized" may just need reframing for a different audience. The same data presented as an RNA biology story (for RNA journal) or a computational methods paper (for Bioinformatics) can look completely different to reviewers who specialize in that area.

A rejection is a chance to improve, not just redirect. Run your revised manuscript through a manuscript scope and readiness check to check formatting, scope alignment, and methodological rigor before your next submission. Catching fixable issues before reviewers do saves months of waiting.

Resubmit to the same tier if:

• Reviewers praised the science but identified specific fixable issues
• The rejection letter suggested "consider resubmission after addressing concerns"
• You can complete the requested revisions within 2-3 months
• No competing paper has appeared since your submission

Move to a different journal if:

• The rejection cited scope mismatch rather than quality concerns
• Multiple reviewers questioned the significance or novelty
• Your timeline requires a decision within the next 2-3 months
• A more specialized journal's readership would value the work more

Reframe the manuscript before resubmitting anywhere if:

• Reviewers identified fundamental methodology problems
• The core argument needs restructuring, not just polishing
• New experiments or analyses are needed to support the claims
• The rejection exposed a gap between claims and evidence

In our pre-submission review work with manuscripts targeting Nucleic Acids Research, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Database or software submissions without documented community utility. NAR's annual Database Issue and Software Issues have specific standards: tools must be publicly accessible, actively maintained, and demonstrate utility for the research community. We see this failure as the most common pattern in NAR tool/database desk rejections we review: repositories submitted without public availability, tools without documentation adequate for independent use, or databases with fewer entries than comparable existing resources would make this new entry necessary. In our review of NAR submissions, we find that editors consistently require demonstrated adoption or compelling differentiation from existing tools before a new resource clears the desk.

Mechanistic claims about nucleic acid structure or function without direct structural or biochemical evidence. NAR expects that mechanistic claims about how DNA, RNA, or nucleic acid-protein complexes function be supported by direct structural or biochemical evidence, not inferred from genetic or sequencing data. We see this pattern in NAR mechanistic submissions we review draw conclusions about molecular mechanisms from genetic experiments or sequence analysis alone without the structural or biochemical data that would directly demonstrate the proposed mechanism.

RNA biology papers outside NAR's molecular and structural scope. NAR focuses on the molecular and structural biology of nucleic acids. Papers reporting RNA-seq expression patterns in disease, clinical associations between RNA biomarkers and patient outcomes, or epidemiological findings about RNA modifications without mechanistic investigation of the nucleic acid biology face consistent scope redirection to molecular medicine or clinical journals. We see this failure regularly in manuscripts we review targeting NAR.

Bioinformatics methods without experimental validation of the computational predictions. NAR publishes computational methods for nucleic acid analysis but requires experimental validation of the tool's predictions on real biological datasets. We see this pattern in bioinformatics submissions we review for NAR present algorithm performance on benchmark datasets without demonstrating that the method's output translates to experimentally verified biological insight.

SciRev community data for Nucleic Acids Research confirms desk rejections typically arrive within days, with post-review first decisions within 6-8 weeks, consistent with the Oxford University Press editorial cadence for this journal.